Strength and nature of the evidence Only one RCT exists, an underpowered single-center trial of just 17 patients comparing PLEX plus immunosuppression versus immunosuppression alone; KDIGO rates the overall quality of evidence as low. [1] Observational/historical-control data drive the recommendation: early mortality fell from ~47% (untreated) to ~8.5% with PLEX plus immunosuppression, and 5-year patient survival now exceeds 90%. [1] Kidney survival improvement: 5-year kidney survival rose from ~25% to ~50% since 2007, attributed to earlier diagnosis and higher proportion treated with PLEX. [1] KDIGO 2021 recommendation (1C) Initiate cyclophosphamide + glucocorticoids + plasmapheresis in all patients with anti-GBM GN, except those who are simultaneously (1) dialysis-dependent at presentation, (2) have 100% crescents or >50% global glomerulosclerosis on adequate biopsy, and (3) lack pulmonary hemorrhage. Patients with alveolar hemorrhage should receive PLEX regardless of renal status, as it is life-saving there. [1-2] Start empirically without delay (within 24 hours) when anti-GBM disease is suspected, before biopsy confirmation. [1][4] Practical protocol Frequency/duration: Daily (or near-daily) single-volume exchanges, typically for 2–3 weeks, continued until anti-GBM antibodies are no longer detectable. [1-2] Replacement fluid: Albumin is generally sufficient, but use fresh frozen plasma (or albumin followed by FFP at the end) in patients with alveolar hemorrhage or recent kidney biopsy to reduce bleeding risk. [1][4] Continuation: Extend if alveolar hemorrhage persists or antibody titers fail to fall or rebound after withdrawal. [2] Prognostic caveats Presenting creatinine drives renal outcome: SCr <5.7 mg/dl → ~95% and ~91% kidney survival at 1 and 5 years; SCr >5.7 mg/dl (non-dialysis) → 82% and 50%; dialysis-dependence at presentation portends poor renal recovery. PLEX is most clearly beneficial in patients with independent kidney function at presentation. [1-3] Selected severe cases may still recover: Case reports describe early, intensive/frequent plasmapheresis continued to complete antibody clearance rescuing kidney function even in anuric patients with high crescent burden, suggesting individualized aggressive treatment can occasionally be worthwhile despite poor-prognosis features. [5] Double-positive (anti-GBM + ANCA) patients should receive PLEX and, unlike classic anti-GBM disease, warrant maintenance immunosuppression given higher relapse risk. [1][3] Emerging therapy: Imlifidase (IgG-degrading enzyme of S. pyogenes) rapidly cleaves circulating IgG including anti-GBM antibodies and is under investigation, though evidence for renal recovery in dialysis-dependent disease remains unestablished; rituximab as an alternative to cyclophosphamide is not yet supported by evidence.
Strength and nature of the evidence
Only one RCT exists, an underpowered single-center trial of just 17 patients comparing PLEX plus immunosuppression versus immunosuppression alone; KDIGO rates the overall quality of evidence as low.
[1]
Observational/historical-control data drive the recommendation: early mortality fell from ~47% (untreated) to ~8.5% with PLEX plus immunosuppression, and 5-year patient survival now exceeds 90%.
[1]
Kidney survival improvement: 5-year kidney survival rose from ~25% to ~50% since 2007, attributed to earlier diagnosis and higher proportion treated with PLEX.
[1]
KDIGO 2021 recommendation (1C)
Initiate cyclophosphamide + glucocorticoids + plasmapheresis in all patients with anti-GBM GN, except those who are simultaneously (1) dialysis-dependent at presentation, (2) have 100% crescents or >50% global glomerulosclerosis on adequate biopsy, and (3) lack pulmonary hemorrhage. Patients with alveolar hemorrhage should receive PLEX regardless of renal status, as it is life-saving there.
[1-2]
Start empirically without delay (within 24 hours) when anti-GBM disease is suspected, before biopsy confirmation.
[1][4]
Practical protocol
Frequency/duration: Daily (or near-daily) single-volume exchanges, typically for 2–3 weeks, continued until anti-GBM antibodies are no longer detectable.
[1-2]
Replacement fluid: Albumin is generally sufficient, but use fresh frozen plasma (or albumin followed by FFP at the end) in patients with alveolar hemorrhage or recent kidney biopsy to reduce bleeding risk.
[1][4]
Continuation: Extend if alveolar hemorrhage persists or antibody titers fail to fall or rebound after withdrawal.
[2]
Prognostic caveats
Presenting creatinine drives renal outcome: SCr <5.7 mg/dl → ~95% and ~91% kidney survival at 1 and 5 years; SCr >5.7 mg/dl (non-dialysis) → 82% and 50%; dialysis-dependence at presentation portends poor renal recovery. PLEX is most clearly beneficial in patients with independent kidney function at presentation.
[1-3]
Selected severe cases may still recover: Case reports describe early, intensive/frequent plasmapheresis continued to complete antibody clearance rescuing kidney function even in anuric patients with high crescent burden, suggesting individualized aggressive treatment can occasionally be worthwhile despite poor-prognosis features.
[5]
Double-positive (anti-GBM + ANCA) patients should receive PLEX and, unlike classic anti-GBM disease, warrant maintenance immunosuppression given higher relapse risk.
[1][3]
Emerging therapy: Imlifidase (IgG-degrading enzyme of S. pyogenes) rapidly cleaves circulating IgG including anti-GBM antibodies and is under investigation, though evidence for renal recovery in dialysis-dependent disease remains unestablished; rituximab as an alternative to cyclophosphamide is not yet supported by evidence.
Created using ChatSlide
This overview discusses the evidence base for treatment outcomes, highlighting a significant reduction in mortality rates and improved survival over five years. It emphasizes the KDIGO recommendation to initiate triple therapy promptly and adjust treatment based on individual bleeding risks. Additionally, it addresses prognosis factors, including creatinine levels and dialysis status, while noting the need for aggressive treatment in severe cases and the investigational status of imlifidase...